NCT00531232View on ClinicalTrials.gov

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 7, 2007

Primary Completion Date

May 12, 2011

Study Completion Date

May 12, 2011

Conditions
Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia (AML)
Interventions
DRUG

Clofarabine

"Pharmaceutical form: Tablet,~Route of administration: Oral"

Trial Locations (6)

10065

Weill Medical College of Cornell University, New York

27157

Wake Forest University Baptist Medical Center, Winston-Salem

44195

Cleveland Clinic, Cleveland

60637

The University of Chicago, Chicago

75246

Baylor University Medical Center Blood Marrow Transplantation Research, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00531232 - A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) | Biotech Hunter | Biotech Hunter